Commercial Supply of Regulated Medical and Defense Items

The contract involves the commercial supply of regulated medical and defense items that must fully comply with the Berry Amendment, ensuring all materials and products are sourced entirely from the United States without any foreign components. Production methods are strictly prohibited from including additive manufacturing, requiring traditional manufacturing processes to meet quality and security standards. Invoicing must be submitted through the Wide Area WorkFlow system, aligning with Department of Defense financial and procurement protocols. The solicitation is issued under NAICS code 325412, indicating pharmaceutical and botanical product manufacturing, and is structured as a subcontract within the broader Medical Supply Chain Pharm FSA framework overseen by the Department of Defense. The place of performance is designated as APO with ZIP code 09094-3219, targeting military logistics and overseas operations. Bids are due by August 3, 2026, and the opportunity was posted on July 28, 2026, with responses expected to demonstrate full regulatory adherence and supply chain compliance under stringent defense acquisition rules.